



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

February 15, 2022

To,
The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub.: Intimation of Newspaper advertisement by Novartis India Limited (“the Company”) regarding the Unaudited Financial Results of the Company for the third quarter ended December 31, 2021

Ref.: Scrip Code - 500672

Dear Sirs,

Apropos the subject matter quoted above, please find enclosed herewith the copies of the newspaper Notices in “Financial Express” and “Navshakti” on February 12, 2022.

This is for your information and record.

Thanking You.

Yours sincerely,

For Novartis India Limited

Noble
Monaz
Digitally signed by Noble Monaz
DN: dc=com, dc=Novartis,
ou=people, ou=IN,
serialNumber=1235335,
cn=Noble Monaz
Reason: I am approving this
document
Date: 2022.02.15 15:07:06 +05'30'

Monaz Noble
Non-Executive Director

Encl.: as above

QUAD MEET

India tough on China, silent on Ukraine, different on Myanmar

SHUBHAJIT ROY
New Delhi, February 11

EXTERNAL AFFAIRS MINISTER S Jaishankar joined counterparts from US, Japan and host Australia at the meeting of Quad foreign ministers in Melbourne Friday to send a clear signal to Beijing, underlining their pursuit of a “shared vision” to uphold “a rules-based international order, free from coercion — one based on respect for territorial integrity and sovereignty”.

But after the meeting, Jaishankar took a slightly nuanced position in public than the three other Foreign Ministers — US Secretary of State Antony J Blinken, Australian Foreign Minister Marise Payne and Japanese Foreign Minister Yoshimasa Hayashi — on at least two important issues: the Russia-Ukraine row and the Myanmar issue.

On Myanmar, Jaishankar pointed to the challenge of insurgency along the Indo-Myanmar border, and recalled the recent incident in which a Colonel and his family that included a child were killed in an ambush by militants. He also stressed that India is against “national sanctions”. The US has imposed sanctions on a number of leaders of the Myanmar junta.

He maintained complete diplomatic silence on the Russian threat to invade Ukraine, while Blinken said there are “troubling signs of Russian escalation, including new forces arriving at the Ukrainian border” and that they are “in a window when an invasion could begin at any time, and that includes during the (Winter) Olympics in Beijing”.

Australia’s Payne expressed “very deep concerns about the Russian military build-up on Ukraine’s border” and Australia’s “strong support for Ukraine’s sovereignty and territorial integrity”.

Japan’s Hayashi said Ukraine was discussed during the Quad meeting and “sovereignty and territorial integrity” have consistently been supported by Japan.

Asked to comment on the recent meeting between Russian President Vladimir Putin and Chinese President Xi Jinping, Jaishankar said: “I would just add that as my colleagues have observed, we are for something, not against somebody.” The issue of Ukraine was not part of the Quad Foreign Ministers’ joint statement either.

Myanmar, however, figured in the joint statement: “We remain gravely concerned about the crisis in Myanmar and call for an end to violence, the



Australian PM Scott Morrison with (from left) Antony Blinken (US), Marise Payne (Australia), S Jaishankar (India) and Yoshimasa Hayashi (Japan) at the Quad meeting of foreign ministers in Melbourne on Friday

PHOTO: AP

release of all those arbitrarily detained, including foreigners, and unhindered humanitarian access. We reaffirm our support for ASEAN efforts to seek a solution in Myanmar and call on the military regime to urgently implement ASEAN’s Five-Point Consensus and swiftly return Myanmar to the path of democracy. We encourage the international community to work together to support an end to the violence.”

After the meeting, Blinken said: “I think it is painfully obvious that the developments there are deeply, deeply troubling, and deeply troubling to all of us. We have seen the junta double down on repression, on violence.”

Jaishankar, in his response to questions, said: “I think we all agreed on the importance of the democratic transition which was underway in Myanmar. And clearly, the fact that the country has moved in a different direction is something which troubles all of us. We all, I think, also very strongly back the ASEAN position on Myanmar and their efforts to engage.”

“But we are concerned, India is concerned as an immediate land-border neighbour. We have some very specific concerns on Myanmar which also guide our thinking, concerns about insurgents operating there who some months ago killed a very senior military officer and his family; concerns about Covid and the lack of vaccination on our common border; concerns about a humanitarian situation which is arising from food shortages.”

“So I think those are also concerns which we take into account, and where we are concerned we don’t follow a policy of national sanctions,” he said, mak-

ing it clear that it doesn’t support US policy on sanctions on Myanmar.

Hayashi confirmed that leaders of the four Quad countries, including Prime Minister Narendra Modi, will be holding a summit in Japan in the first half of this year.

Jaishankar said: “As leading democracies, we pursue our shared vision of upholding a rules-based international order, free from coercion — one based on respect for territorial integrity and sovereignty, rule of law, transparency, freedom of navigation in the international seas and peaceful resolution of disputes.”

The Quad statement also talked about “terrorism and violent extremism” and stated: “We denounce the use of terrorist proxies for cross-border terrorism and urge countries to work together to eliminate terrorist safe havens; disrupt terrorist networks and the infrastructure and financial channels which sustain them; and halt cross-border movement of terrorists.”

In this context, we call on all countries to ensure that territory under their control is not used to launch terror attacks and to expeditiously bring to justice the perpetrators of such attacks.”

“We reiterate our condemnation of terrorist attacks in India, including 26/11 Mumbai and Pathankot attacks,” it said, adding that they reaffirmed UNSC Resolution 2593 (2021) that “Afghan territory should not be used to threaten or attack any country, shelter or train terrorists, or plan or finance terrorist acts, with such ungoverned spaces being a direct threat to the safety and security of the Indo-Pacific”.

Voltas Q3 profit declines 25% to ₹97 cr on muted demand

PRESS TRUST OF INDIA
New Delhi, February 11

VOLTAS ON FRIDAY reported 24.93% decline in consolidated net profit to ₹96.56 crore for December quarter 2021-22 on account of muted demand and

impact of the third wave of the pandemic on trade and consumer sentiments.

The Tata group firm had posted a consolidated net profit of ₹128.64 crore for the year-ago period, Voltas said in a regulatory filing.

Revenue from operations was down at ₹1,793.59 crore during the period under review as against ₹1,994.64 crore.

“While muted demand post season and early signs of third wave (Omicron) has impacted the trade and consumer sentiments

for the cooling products segment, better execution efficiencies in some of the ongoing projects improved the results (profitability) of Electro-Mechanical Projects and Services segment over the corresponding quarter last year,” said Voltas in its earning statement.

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE: New No.103 (Old No.42-45), Luz Church Road, Mylapore, Chennai-600 004
email id: investors@amrutanjan.com | website: www.amrutanjan.com | CIN No: L24231TN1936PLC000017



EXTRACT FROM THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021



(Rs. In lakhs other than EPS)

Particulars	Quarter ended			Period Ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	11,069.59	11,038.20	10,009.70	29,928.94	23,882.72	33,284.40
Net Profit / (Loss) for the period (before Tax, Exceptional and /or Extraordinary items)	2,791.50	2,635.61	2,814.31	7,055.73	6,819.30	8,190.45
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	2,791.50	2,635.61	2,814.31	7,055.73	6,819.30	8,190.45
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	2,057.78	1,984.78	2,098.56	5,248.30	5,096.16	6,119.04
Total Comprehensive Income for the period (comprising Profit / (loss) for the period (after tax) and Other comprehensive income (after tax))	2,033.54	1,945.05	2,077.33	5,181.74	5,088.68	6,116.24
Equity Share Capital	292.31	292.31	292.31	292.32	292.31	292.31
Reserves (excluding Revaluation Reserve)	21,264.16 (As on 31-03-2021)	21,264.16 (As on 31-03-2021)	15,650.25 (As on 31-03-2020)	21,264.16 (As on 31-03-2021)	15,650.25 (As on 31-03-2020)	21,264.16 (As on 31-03-2021)
Earnings Per Share (Rs.1/- each)						
Basic	7.05	6.79	7.18	17.97	17.43	20.94
Diluted	7.03 (not annualised)	6.77 (not annualised)	7.18 (not annualised)	17.92 (not annualised)	17.43 (not annualised)	20.93 (annualised)

Note :

- The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine months ended Financial Results are available on the Stock Exchange websites www.bseindia.com and www.nseindia.com and on the Company's website www.amrutanjan.com.
- The above financial results for the quarter and nine months ended 31st December 2021 in respect of Amrutanjan Health Care Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 11th February 2022. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.
- The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS), 34 - "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 (the Act), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015.
- Interim Dividend of Re. 1/- per share, aggregating to INR. 292.31 lakhs has been paid during the quarter ended 31st December 2021.

Place : Chennai
Date : 11th February 2022

For Amrutanjan Health Care Limited
-s/d/
S. Sambhu Prasad
Chairman & Managing Director

Godrej Industries reports Q3 net profit at ₹183 cr

PRESS TRUST OF INDIA
New Delhi, February 11

GODREJ INDUSTRIES ON Friday reported a profit after tax of ₹182.78 crore for the third quarter ended December 2021 and announced investment of up to ₹2,500 crore in two subsidiaries Godrej Properties and Godrej Agrovet.

The company had posted a net profit of ₹170.66 crore in the October-December quarter a year ago, Godrej Industries (GI) said in a BSE filing.

Its revenue from operations was at ₹3,514.61 crore during the quarter. It stood at ₹2,356.47 crore in the corresponding quarter last fiscal year. Total expenses were at ₹3,510.03 crore.

Godrej Industries said its results are “not comparable with those of the previous periods/year” in view of acquisitions and changes in the company’s/ group’s shareholding during the period in some of the subsidiaries, joint ventures and associates.

Godrej Industries further said its

board has approved a further investment of up to ₹2,000 crore in Godrej Properties by way of subscription and purchase of securities or otherwise.

It has also approved an investment of up to ₹500 crore in Godrej Agrovet.

Shares of Godrej Industries on Friday settled at ₹570.65 on the BSE, down 2.06% from the previous close.

NOVARTIS NOVARTIS INDIA LIMITED			
Registered Office: Inspire BKC, Part of 601 & 701, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Maharashtra, India. Tel.: +91 22 50243000; Fax: +91 22 50243010; Email: india.investors@novartis.com; Website: www.novartis.in; CIN: L24200MH1947PLC006104			
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2021			
(₹ in Million)			
Particulars	3 months ended 31.12.2021 (Unaudited)	9 months ended 31.12.2021 (Unaudited)	3 months ended 31.12.2020 (Unaudited)
Total Income	1,050.0	3,204.3	1,020.3
Net Profit for the period before tax	83.9	275.3	6.8
Net Profit/(Loss) for the period after tax	63.5	196.5	(7.1)
Total Comprehensive income/(loss) for the period (comprising profit/(loss) for the period after tax and other comprehensive income after tax)	63.5	257.6	(28.3)
Equity Share Capital (of ₹ 5 each, fully paid)	123.4	123.4	123.4
Earnings Per Share (of ₹ 5 each) (*not annualised)			
Basic and Diluted (₹)	2.57 *	7.96 *	(0.29)*

Note:

- The above is an extract of the detailed format of Financial Results for the quarter and nine months ended 31st December 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the quarter and nine months ended 31st December 2021 are available on the stock exchange website, www.bseindia.com and on the Company's website, www.novartis.in

By Order of the Board
Sanjay Murdeshwar
Vice Chairman and Managing Director
DIN: 01481811

Place: Mumbai
Date : 10th February, 2022
Financial Express



RAM RATNA WIRES LIMITED

(CIN: L31300MH1992PLC067802)

Regd. Office: Ram Ratna House, Oasis Complex, P.B.Marg, Worli, Mumbai 400 013
Tel: +91 - 22 - 2494 9009/ 2492 4144 ♦ Email Id: investorrelations@rrglobal.com ♦ Website: www.rrshramik.com

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(₹ in lakhs)

Sr. No.	Particulars	STANDALONE			CONSOLIDATED						
		Quarter Ended		Year Ended	Quarter Ended		Year Ended				
		31.12.2021	31.12.2020	31.03.2021	31.12.2021	31.12.2020	31.03.2021				
1.	Total Income from operations (net)	51515.69	39616.72	144866.02	89137.29	138698.12	60283.28	43669.12	165138.59	97814.90	152694.26
2.	Net Profit for the period/year before tax	2005.65	752.72	4473.31	658.43	1788.76	2311.12	988.25	5033.65	716.39	2115.47
3.	Net Profit for the period/year after tax (Share of Owners of the Company)	1462.80	538.27	3304.82	482.55	1351.00	1588.90	658.27	3569.52	512.01	1490.05
4.	Total Comprehensive Income for the period/year [Comprising profit for the period/ year (after tax) and Other Comprehensive Income (after tax)] (Share of Owners of the Company)	1643.01	985.87	5338.14	1253.06	2129.16	1771.54	1102.12	5604.07	1270.80	2258.60
5.	Equity Share Capital	1100.00	1100.00	1100.00	1100.00	1100.00	1100.00	1100.00	1100.00	1100.00	1100.00
6.	Reserves excluding Revaluation Reserves as at Balance Sheet date					18642.39					18925.90
7.	Basic & Diluted Earnings per share (of ₹ 5/- each)*	6.65	2.45	15.02	2.19	6.14	7.22	2.99	16.23	2.33	6.77

*Basic and Diluted Earnings per share are not annualised except for the year ended 31st March, 2021.

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2022.
- The above is an extract of the detailed format of Statement of Standalone and Consolidated Financial Results filed with the Bombay Stock Exchange (BSE) under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Standalone and Consolidated Financial Results are available on the BSE website www.bseindia.com and on Company's website www.rrshramik.com

For and on behalf of the Board of Directors of
RAM RATNA WIRES LIMITED

Sd/-
Tribhuvanprasad Kabra
Chairman
DIN: 00091375

Place : Vadodara
Dated : 11th February, 2022

महालक्ष्मी सिमलेस लिमिटेड
 पार्टिपनर (मुक्ती) व्हाय नागोदाण, तालुका रोहा, जि. रायगड, महाराष्ट्र-४०२१२६.
 सीआयएन: एल१३०००एमएच११११पीएलसी०६१३४४; ईमेल आयडी: vivekjalani@mahaubes.com

तपशील	संपलेले ३ महिने (रु. लाखात)			नऊ महिने
	३१ डिसेंबर - २०२१	३१ डिसेंबर - २०२०	३१ डिसेंबर - २०२१	
(खालील टीपा च्या)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	
प्रवर्तनातून एकूण उत्पन्न	५५.१५	४५.०३	१५८.१२	
संशोधन कर्मकांडातून कोसट निव्वळ नफा/(तोटा)	१३.०९	४.०९	३१.०८	
कालावधीसाठी कोसट निव्वळ नफा/(तोटा)	६३.०६	४९.०९	१८७.०४	
(अनन्य साधारण बाबींचा)				
समाप्त भांडवल (रु. १०/- प्रती समाप्त)	५२८.१४	५२८.१४	५२८.१४	
प्रती समाप्त प्रामी	०.२५	०.०८	०.५९	
(१) मूलभूत	०.२५	०.०८	०.५९	
(२) सोमिकृत	-	-	-	

टीप: वरील माहिती म्हणजे सेबी (लिस्टिंग अँड अरर डिस्क्लोजर रिक्वायर्मेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजकडे सादर केलेल्या तिमाही निष्कर्षांच्या तपशीलावर विवचनाचा एक उतारा आहे. तिमाही निष्कर्षांचे संपूर्ण विवरण स्टॉक एक्सचेंजची वेबसाईट (युआरएल अफ फॉरवर्डिंग) वर उपलब्ध आहे.

महालक्ष्मी सिमलेस लि. साठी
 चिकित्सा जालन - व्यवस्थापकीय संचालक
 (डीआयएन: ०९१४३७५५)

ठिकाण: मुंबई
 दिनांक: ११/०२/२०२२

JOYVILLE SHAPOORJI HOUSING PRIVATE LIMITED
 CIN : U70109MH2007PTC166942 | Website: www.joyvillehomes.com
 Registered Office: SP Centre, 41/44, Minoo Desai Marg, Colaba, Mumbai - 400005

Statement of Unaudited financial results for the three months ended 31 December 2021

Sr. No.	Particulars	3 months ended		Previous year ended
		31-Dec-21	31-Mar-21	
		(Unaudited) INR in lakhs	(Audited) INR in lakhs	
1	Revenue from operations	10,943.22	12,691.16	
2	Net (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(2,305.92)	(4,952.11)	
3	Net (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(2,305.92)	(4,952.11)	
4	Net (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(2,305.92)	(4,952.11)	
5	Total Comprehensive Income for the period [Comprising (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(2,292.62)	(4,946.94)	
6	Paid-up equity share capital (Face Value of the equity share INR 10 each)	10.31	10.31	
7	Reserves (excluding Revaluation Reserves)	(25,051.17)	(20,165.95)	
8	Securities Premium Account	-	-	
9	Net worth	(25,040.86)	(20,155.64)	
10	Paid up debt capital	1,18,809.55	115,606.56	
11	Outstanding Redeemable Preference Shares	-	-	
12	Debt Equity ratio	(5.31)	(7.04)	
13	Earnings per share (Face value of INR 10/- each)			
	(a) Basic (INR)	(2,236.76)	(4,803.58)	
	(b) Diluted (INR)	(2,236.76)	(4,803.58)	
14	Capital Redemption Reserve	-	-	
15	Debtenture Redemption Reserve	-	-	
16	Debt Service Coverage ratio	(0.24)	(0.13)	
17	Interest Service Coverage ratio	(0.40)	(0.21)	

Notes:
 a. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results is available on the website of the Stock Exchange viz. www.bseindia.com. The same is also available on the Company's website viz. www.joyvillehomes.com.
 b. For the other line items referred in Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com.
 c. In accordance with the SEBI circular dated October 5, 2021 the Company has availed an exemption w.r.t. presentation of corresponding quarterly financial results for the quarter ended 31 December 2020.

For and on behalf of the Board of Directors of Joyville Shapoorji Housing Private Limited
 CIN : U70109MH2007PTC166942
 sd/-
Sriram Mahadevan
 Managing Director
 DIN: 08028238

Place : Gurugram
 Date : 10 February 2022

PUBLIC NOTICE
 We, Kotak Mahindra Bank Limited, (KMBL), for our Banking and other related business including setting up its Bank Branch, Automated Teller Machine (ATM) desire to take on License the properties for 15 (Fifteen) years, more particularly described in the schedule hereunder written, from the owners herein below. People at large and all the concerned, private individuals, government/semi-government institutions / bodies / authorities, if has got any right, title, interest, or share in property herein mentioned or anybody who has objection for the aforesaid transaction are hereby publicly informed to raise their objections in writing with copies of all the supportive documents to the undersigned within 7 (seven) days from publication of this public notice. If the objections are not received by the undersigned in writing along with copies of all supportive documents within 7 (seven) days from publication of this public notice, then it will be construed that the title to the said property are clear and that all such concerned have waived their rights and all such concerned shall be estopped from raising any objections thereafter and that we shall proceed thereafter further for the execution of the Leave and License Agreement or such agreements and all such persons shall be estopped from raising any objections to such transaction thereafter.

Schedule of the Property

Description of the Properties to be taken on License	Owner/Proposed Licensor
Commercial Premises being Shop Nos 8 & 9, collectively addressing about 1350 sq.ft. carpet area (approx.) on the Ground floor and an area addressing about 330 sq.ft. carpet area on the Mezzanine Floor of the building known as Highway Heights, B-Wing, Warje, Pune-411038, having Survey No.112, Hissa No.1+2+3/21/21, and 2/47 (New Survey No. 112/2A/1 and 112/2/47) Village Warje, Taluka Haveli, District Pune, within the limits of Pune Municipal Corporation.	Mrs. Kalyani Kulkarni and Mr. Jilendra Kulkarni both residing at Yojirga Bunglows, Plot No. 3, Gukul Housing Society, Near Mhatre Road, Navi Path, Pune-411030.

SW INVESTMENTS LIMITED
 Regd. Office: 5th Floor, Suntek Centre, 37-40 Subhash Road, Vile Parle (East), Mumbai 400057
 CIN:L65990MH1980PLC023333
 Website: www.swindia.com Email: cosec@swindia.com Tel: +91 224287 7800

Extract of Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2021

Sr. No.	Particulars	Quarter ended		
		31.12.2021	31.12.2021	31.12.2020
		Unaudited	Unaudited	Unaudited
PART I				
1.	(a) Total Income from Operations	1.29	2.82	0.80
	(b) Other Income	0.51	50.35	11.62
	Total Income (a + b)	1.80	53.17	12.42
2.	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	(3.46)	37.57	6.37
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(3.46)	37.57	6.37
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(2.58)	28.12	7.28
5.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(2.58)	104.58	7.28
6.	Paid up equity share capital (Face Value of Re. 10 each)	90.00	90.00	90.00
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-
8.	Earnings per share (of Re. 10 each) (not annualised) (for continuing and discontinued operations)			
	a) Basic	(0.29)	3.12	0.81
	b) Diluted	(0.29)	3.12	0.81

Notes to the financial results:
 1. The above unaudited financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on February 11, 2022. The unaudited financial results for the quarter and nine-months ended on December 31, 2021 have been subjected to Limited Review by the Statutory Auditors.
 2. The above is an extract of the detailed format of Financial Results for the quarter and nine-months ended on December 31, 2021 filed with the Stock Exchange under Regulation 33 of SEBI LODR. The full format of the Financial Results for the quarter and nine-months ended on December 31, 2021 are available on the Stock Exchange website (www.bseindia.com) and Company's website (www.swindia.com).

For and on behalf of Board of Directors of SW Investments Limited
 sd/-
Lalitha Cheripalli
 Director (DIN: 07026989)

Date : February 11, 2022
 Place : Mumbai

SHIRPUR GOLD REFINERY LIMITED
 Regd. Office : Refinery Site, Shirpur, Dist. Dhule, Maharashtra- 425405
 CIN : L15100MH1984PLC034501
 www.shirpurgold.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31st December, 2021 (Rs. in Lakhs except per share data)

Particulars	STANDALONE			CONSOLIDATED		
	Quarter ended	Quarter ended	Nine Months	Quarter ended	Quarter ended	Nine Months
	31-Dec-21	31-Dec-20	Ended 31-12-2021	31-Dec-21	31-Dec-20	Ended 31-12-2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1. Total Income from Operations	-	-	1,135,633.95	153,227.03	-	397,930.91
2. Net Profit / (Loss) for the period (before tax, exceptional and/or extraordinary items)	(1,573.34)	(6,438.08)	(6,601.34)	(1,174.77)	(6,268.82)	(5,648.70)
3. Net Profit / (Loss) for the period before tax (after exceptional and/or extraordinary items)	(1,573.34)	(6,438.08)	(8,944.72)	(1,174.77)	(6,268.82)	(7,992.08)
4. Net Profit / (Loss) for the period after tax (after exceptional and/or extraordinary items)	(1,573.34)	(6,438.08)	(8,944.72)	(1,174.77)	(6,268.82)	(7,992.08)
5. Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-	-	-	-	-	-
6. Paid-up equity share capital	2,913.72	2,913.72	2,913.72	2,913.72	2,913.72	2,913.72
7. Earning Per Share (of Rs. 10/- each) (for continuing and discontinued operations)	(5.40)	(22.10)	(30.70)	(4.03)	(21.51)	(27.43)
2. Diluted	(5.40)	(22.10)	(30.70)	(4.03)	(21.51)	(27.43)

Notes : 1. The above is an extract of the detailed format of quarter ended financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. 2. The full format of the aforesaid quarter ended financial results are available on the Stock Exchange website www.nseindia.com and www.bseindia.com respectively and Company's website at www.shirpurgold.com

For and on behalf of the Board of Directors
Prakash Chandra Pandey
 Director

Place: Mumbai
 Date: 10th February 2022

NOVARTIS
नोवार्टिस इंडिया लिमिटेड

नोंदणीकृत कार्यालय: इन्व्हायर्स बिल्डींग, ६०१ व ७०१ चा भाग, वाये कुर्ला संजुल, वांद्रे (पूर्व), मुंबई-४०० ०११ महाराष्ट्र, भारत
 फोन नं.: +९१ २२ ५०२४३००० फॅक्स: +९१ २२ ५०२४३०१०;
 ईमेल: india.investors@novartis.com, संकेत स्थळ: www.novartis.in
 सीआयएन: एल४४२००एमएच११४७पीएलसी००६१०४

३१ डिसेंबर, २०२१ रोजी संपलेल्या तिमाही आणि नऊ माहीचे अलेखापरीक्षित वित्तीय निष्कर्षांचा सारांश

तपशील	₹ दशलक्षामध्ये		
	३१.१२.२०२१ रोजी संपलेली तीन महिने (अ-लेखापरीक्षित)	३१.१२.२०२१ रोजी संपलेली नऊ महिने (अ-लेखापरीक्षित)	३१.१२.२०२० रोजी संपलेली तीन महिने (अ-लेखापरीक्षित)
एकूण उत्पन्न	१,०५०.०	३,२०४.३	१,०२०.३
कालावधीकरिता कर्पूर निव्वळ नफा	८३.९	२७५.३	६.८
कालावधीकरिता करोत्तर निव्वळ नफा/(तोटा)	६३.५	१९६.५	(७.९)
कालावधीकरिता एकूण व्यापक उत्पन्न/(तोटा) (कालावधीकरिता करोत्तर नफा/(तोटा) आणि करोत्तर इतर व्यापक उत्पन्न यांचा समावेश)	६३.५	२५७.६	(२८.३)
समभाग भांडवल (प्रत्येकी ₹ ५ चे, पूर्णपणे भरणा झालेले)	१२३.४	१२३.४	१२३.४
प्रति भाग प्रामी (प्रत्येकी ₹ ५ चे) (* वार्षिक नाही)	२.५७ *	७.९६ *	(०.२९) *
बेसिक आणि डायल्यूटेड (₹)	२.५७ *	७.९६ *	(०.२९) *

टीप:
 १. सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायर्मेंट्स) रेग्युलेशन्स २०१५ च्या नियमावली ३३ अंतर्गत स्टॉक एक्सचेंजकडे ३१ डिसेंबर, २०२१ रोजी सादर केलेल्या तिमाही आणि नऊमाहीचे आर्थिक निष्कर्षांच्या तपशीलावर नमुन्याचा वरील उल्लेख केलेला सारांश आहे. ३१ डिसेंबर, २०२१ रोजी तिमाही आणि नऊमाहीचे आर्थिक निष्कर्षांचा संपूर्ण नमुना स्टॉक एक्सचेंजच्या www.bseindia.com या संकेतस्थळावर आणि www.novartis.in या कंपनीच्या संकेतस्थळावर उपलब्ध आहेत.

मंडळाच्या आदेशानुसार
 संचाय मुरदेश्वर
 उपाध्यक्ष आणि व्यवस्थापकीय संचालक

स्थळ : मुंबई
 दिनांक : १० फेब्रुवारी, २०२२

ebnl Emmessar Biotech & Nutrition Ltd.
 Registered Office: Plot No.T-3/2, MIDC, Talaja, Raigad Dist., Maharashtra - 410 208.
 CIN: L24110MH1992PLC06594229

UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2021 (₹ in Lakhs)

Sr. No.	Particulars	Unaudited					Audited
		Quarter Ended		Nine months Ended		Year ended	
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
I	Revenue from Operations	15.95	3.58	110.70	21.85	247.00	699.08
II	Other Income	40.75	42.71	54.08	121.27	110.28	146.56
III	Total Income (I + II)	56.70	46.29	164.78	143.12	357.28	845.64
IV	Expenses						
	Cost of material consumed	1.36	0.69	67.61	2.07	85.10	251.97
	Purchase of Stock-trade	9.72	0.00	0.00	9.72	4.80	12.14
	Change in Inventories of Finished goods	(6.16)	0.22	(23.75)	(5.09)	38.20	89.12
	Employee Benefit Expenses	23.65	17.66	19.74	59.26	46.14	63.84
	Depreciation & Amortisation of Assets	2.65	1.85	1.44	5.55	4.31	5.77
	Other Expenditure	8.90	7.52	54.61	27.54	85.88	197.35
	Total Expenses (IV)	39.78	27.94	119.65	99.05	264.43	620.19
V	Profit / (loss) from Operations before tax (III - IV)	16.92	18.35	45.13	44.07	92.85	225.45
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax	16.92	18.35	45.13	44.07	92.85	225.45
VIII	Tax Expense	-	-	-	-	-	-
	1. Current Tax (MAT)						(47.00)
	2. Deferred Tax						(44.76)
	3. MAT Credit						6.25
	4. Excess / (short) provision of earlier years	0.00	0.00	0.07	0.00	(0.53)	5.03
IX	Net Profit / (loss) after tax (V - VII)	16.92	18.35	45.06	44.07	93.38	144.97
X	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	(1.14)
XI	Total comprehensive income and Other Comprehensive Income	16.92	18.35	45.06	44.07	93.38	143.83
XII	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00	10.00	10.00
	Earning per Shares						
	Basic	0.34	0.37	0.90	0.88	1.87	2.88
	Diluted	0.34	0.37	0.90	0.88	1.87	2.88

Notes:
 1. The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 11th February 2022 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
 2. The Company operates two segments i.e. Healthcare and Rent on Leasehold Land.
 3. Deferred tax & provision for taxation will be calculated annually.
 4. No Investors Complaint received during the quarter ended 31st December 2021

Segmentwise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st Dec 2021

Sr. No.	Particulars	Unaudited					Audited
		Quarter Ended		Nine Months Ended		Year Ended	
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
1	Segment Revenue						
a	Healthcare	15.95	3.58	2.80	21.85	21.13	68.97
b	Fine Chemicals	0.00	0.00	107.90	0.00	225.87	630.10
c	Rent on leasehold land	33.78	33.78	51.27	101.34	101.34	135.13
d	Others	6.97	8.93	2.81	19.93	8.94	11.43
	Total:	56.70	46.29	164.78	143.12	357.28	845.63
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Net Sales / Income from Operations	56.70	46.29	164.78	143.12	357.28	845.63
2	Segment Results (Profit / Loss) before tax						
a	Healthcare	10.70	2.35				